Evercore ISI lowered the firm’s price target on Denali Therapeutics to $50 from $80 and keeps an Outperform rating on the shares, citing a "growing appreciation of how long it will take for trials of interest to read-out and support approval." The firm’s pushed out launch timeline expectations drive its lower price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- 3 Stocks to Buy Today, 2/28/2023, According to Top Analysts
- Denali Therapeutics price target lowered to $38 from $46 at Wedbush
- Denali Therapeutics reports Q4 EPS (75c), consensus (79c)
- Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™